Las pamoras, sus utilidades y avances en el tratamiento de los efectos colaterales de los opioides en los receptores mu

Palabras clave

Analgésicos opioides
Trastornos relacionados con opioides
Receptores opioides mu Analgesics
Opioid-related disorders

Cómo citar

Daza Barriga, J., & Ruiz Pérez, O. (2011). Las pamoras, sus utilidades y avances en el tratamiento de los efectos colaterales de los opioides en los receptores mu. Biociencias, 6(2), 73–82. Recuperado a partir de


El objetivo del presente trabajo es revisar el estado de conocimientos sobre las utilidades de sustancias antagó- nicas de receptores mu de acción periférica (pamoras), en el tratamiento de los efectos colaterales de opiáceos relacionados con los receptores mu. Se realizó una búsqueda de literatura entre 2001-2010, a partir de la cual se concluye que las pamoras, particularmente la metilnaltrexona y el alvimopan han mostrado utilidad en el trata- miento de efectos gastrointestinales, hasta el punto que su uso ha sido aprobado por la Food and Drug Administra- tion. Probablemente otros efectos indeseables de los opiáceos tales como: retención urinaria, náuseas y prurito puedan ser tratados con estas sustancias, pero se requiere investigación adicional. Además, en la actualidad se estudian intensamente los efectos de las pamoras sobre otras acciones celulares no deseables de los opiáceos, tales como crecimiento tumoral y aumento de la permeabilidad vascular. Las acciones son mediadas por antago- nismo en receptores mu periféricos.



1.Schwartz AJ, Moss J, Foss J. Pain relief without side effects: peripheral opiate antagonists. In: Schwartz AJ, ed. ASA Refresher Courses in Anesthesiology. Vol Philadelphia, PA: Lippin- cott Williams and Wilkins. 2005:175-86.

2.Moss J. Rosow CE. Development of peri- pheral opioid antagonists: New Insights Into Opioid Effects. Mayo Clin Proc. 2008; 83(10):1116-30.

3.US Food and Drug Administration. FDA ap- proves Relistor for opioid-induced constipa- tion. [homepage on the Internet]. Maryland; [updated 2008 April 24; cited 2008 Aug 29]. Available from: pics/NEWS/2008/NEW01826.html

4.US Food and Drug Administration. FDA appro- ves Entereg to help restore bowel function following surgery. [homepage on the In- ternet]. Maryland; [updated 2008 May 20; cited 2008 Aug 27]. Available from: http:// NEW01838.html

5.Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid boweldys function and other opioid adverse effects. Ann Pharmacother. 2007; 41(6):984-93.

6.Büchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal sur- gery: results of an international randomized, double-blind, multicentre, placebo-contro- lled clinical study. Aliment Pharmacol Ther. 2008;28: 312-25.

7.Cassel JA, Daubert JD, DeHaven RN. [(3) H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005; 520(1-3):29-36.

8.Doyle D, Hanks G, Cherry N, Calman K, Sykes N. Constipation and diarrhoea. In: Doyle D, Hanks G, Cherry N, Calman K, eds. Oxford Textbook of Palliative Medicine. 3rd ed. New York, NY: Oxford University Press; 2004:483-96.

9.Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al. Alvimopan Posto- perative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioide antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005; 48(6):1114-25.

10.Leslie J, Bell T, Annunziata K, Freedman D. Opioid-induced constipation compromises pain management and impacts patient quali- ty of life. Anesthesiology. 2006; 105: A1490. 11.Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic techni- que for radical prostatectomy surgery affects cancer recurrence: a retrospectivwe analy- sis. Anesthesiology. 2008; 109(2):180-87.

12.Exadaktylos AK, Buggy DJ, Moriarty DC, Mas- cha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect re- currence or metastasis?. Anesthesiology. 2006;105 (4):660-64.

13.Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S-18S.

14.Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001; 182(5A)(suppl):3S- 10S.

15.Kurz A, Sessler DI. Opioid-induced bowel dys- function: pathophysiology and potential new therapies. Drugs. 2003; 63(7):649-71.

16.Maron DJ, Fry RD. New therapies in the treatment of postoperative ileus after gas- trointestinal surgery. Am J Ther. 2008; 15(1):59-65.

17.Shook JE, Pelton JT, Hruby FJ, Burks TF. Pep- tide opioid antagonist separates peripheral and central opioid antitransit effects. J Phar- macol Exp Ther. 1987; 243(2):492-500.

18.Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Dis- covery of a potent, peripherally selective trans-3,4-dimethyl-4-(3- hydroxyphenyl) pi- peridine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994; 37(15):2262-65.

19.Yuan CS, Doshan H, Charney MR, O’connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methyl- naltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005; 45(5):538-46.

20.Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia redu- ce the risk of recurrence after breast cancer? methodology of a multicenter randomized trial. Contemp Clin Trials. 2008; 29(4):517-26.

21.Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-me- diated enhancement of HIV infection of hu- man blood mononuclear phagocytes. J Phar- macol Exp Ther. 2003; 307(3):1158-62.

22.Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, et al. HIV-1 variation be- fore seroconversion in men who have sex with men: analysis of acute/early HIV infec- tion in the multicenter AIDS cohort study. J Infect Dis. 2008; 197(7):1011-15.

23.Keele BF, Giorgi EE, Salazar-Gonzalez JF, Dec- ker J, Pham K, Salazar M, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 in- fection. Proc Natl Acad Sci U S A. 2008; 105 (21):7552-57.


Los datos de descargas todavía no están disponibles.